Diabetes: Echo Therapeutics sends pre-submission package to FDA for Symphony needle-free CGM

June 17, 2013 by Brian Johnson

Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-invasive, wireless continuous glucose monitor.

Diabetes: Echo Therapeutics sends pre-submission package to FDA for Symphony needle-free CGM

Philadelphia-based Echo Therapeutics (NSDQ:ECTE) said it's taken another step toward obtaining FDA approval for its non-invasive, wireless continuous glucose monitoring system.

In regulatory filings, company officials said they submitted a pre-submission package to the FDA for its Symphony CGM System for use in the hospital critical care environment, requesting a meeting with the watchdog agency to determine the best regulatory pathway.

"As the company now begins to sharpen its focus on gaining FDA approval, we are committed to obtaining as much FDA input and agreement as possible regarding the design of the pivotal trial. The pre-submission with the FDA is a significant milestone on our path to advance Symphony towards U.S. commercialization. Following the feedback we expect to receive from our meeting with the FDA, we plan to initiate the pivotal U.S. clinical trial for Symphony," Echo Therapeutics CEO Patrick Mooney said in prepared remarks.

Sign up to get our free newsletters delivered right to your inbox.

The company announced June 5 that it launched a multi-center clinical trial in support of CE Mark submission to European regulators, expecting results during the 3rd quarter.

ECTE shares were down 1.1% to $2.75 each as of about 11:10 a.m. today.

Comments